Simvastatin Inhibits Glucose-Stimulated Vascular Smooth Muscle Cell Migration Involving Increased Expression of RhoB and a Block of Ras/Akt Signal

Cardiovascular Therapeutics

Volumn 30, Issue 2, 2012, Pages 75-84

  Chan, Kuei Chuan ^a   Wu, Cheng Hsun ^b   Huang, Chien Ning ^a   Lan, Kuang Ping ^c   Chang, Wen Chun ^d   Wang, Chau Jong ^d  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Kaomei College of Health Care and Management   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

PI3K Akt; RhoB; Simvastatin; Vascular smooth muscle cell migration

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVALONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN;

ANIMAL CELL; ARTICLE; CELL MIGRATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDICATORS AND REAGENTS; MATRIX METALLOPROTEINASES; MEVALONIC ACID; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RATS; RHOB GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIMVASTATIN; WOUND HEALING;

EID: 84863230568     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00226.x     Document Type: Article

References (53)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
2. Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551-2556.
3. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-2089.
4. Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 2003;278:35049-35056.
5. Campbell M, Allen WE, Sawyer C, Vanhaesebroeck B, Trimble ER. Glucose potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res 2004;95:380-388.
6. Graier WF, Grubenthal I, Dittrich P, Wascher C, Kostner GM. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 1995;294:221-229.
7. Hattori Y, Hattori S, Sato N, Kasai K. High-glucose-induced nuclear factor κB activation in vascular smooth muscle cells. Cardiovasc Res 2000;46:188-197.
8. Inoue T, Node K. Vascular failure: A new clinical entity for vascular disease. J Hypertens 2006;24:2147-2148.
9. Koh KK. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648-657.
10. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999;99:354-360.
11. Merten M, Dong JF, Lopez JA, Thiagarajan P. Cholesterol sulfate: A new adhesive molecule for patients. Circulation 2001;103:2032-2034.
12. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-251.
13. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
14. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935.
15. Strandberg TE, Vanhanen H, Tikkanen MJ. Effects of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999;353:188-189.
16. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999;353:1274.
17. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999;100:230-235.
18. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
19. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002;36:150-157.
20. Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res 2008;58:247-256.
21. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-19928.
22. Kundra V, Anand-Apte B, Feig LA, Zetter BR. The chemotactic response to PDGF-BB: Evidence of a role for Ras. J Cell Biol 1995;130:725-731.
23. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999;84:1186-1193.
24. Takai Y, Sasaki T, Tanaka K, Nakanishi H. Rho as a regulator of the cytoskeleton. Trends Biochem Sci 1995;20:227-231.
25. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997;11:2295-2322.
26. Fritz G, Kaina B. Rhob encoding a UV-inducible ras-related small gtp-binding protein is regulated by GTPases of the rho family and independent of jnk, erk, and p38 map kinase. J Biol Chem 1997;272:30637-30644.
27. Jähner D, Hunter T. The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 1991;11:3682-3690.
28. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-269.
29. Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem 1995;270:7864-7868.
30. Baron R, Fourcade E, Lajoie-Mazenc I, et al. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: Evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA 2000;97:11626-11631.
31. Perona R, Montaner S, Saniger L, Sánchez-Pérez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997;11:463-475.
32. Fritz G, Kaina B. Ras-related GTPase Rhob represses NF-kappaB signaling. J Biol Chem 2001;276:3115-3122.
33. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:e83-e88.
34. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998;435:29-34.
35. van Leeuwen RTJ. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrionolysis 1996;10:59-74.
36. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, Krymskaya VP. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L354-L363.
37. Khwaja A. Akt is more than just a Bad kinase. Nature 1999;401:33-34.
38. Lai P, Michelangeli F. Changes in expression and activity of the secretory pathway Ca2+ ATPase 1 (SPCA1) in A7r5 vascular smooth muscle cells cultured at different glucose concentrations. Biosci Rep 2009;29:397-404.
39. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 1999;99:1370-1378.
40. Zhu L, Sun G, Zhang H, et al. PGC-1alpha is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cells. PLoS One 2009;4:e4182.
41. Inoue T, Node K. Statin therapy for vascular failure. Cardiovasc Drugs Ther 2007;21:281-295.
42. Koch G, Benz C, Schmidt G, Olenik C, Aktories K. Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther 1997;283:901-909.
43. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271.
44. Horn MP, Knecht SM, Rushing FL, et al. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 2008;326:135-143.
45. Stamatakis K, Cernuda-Morollón E, Hernández-Perera O, Pérez-Sala D. Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway. J Biol Chem 2002;277:49389-49396.
46. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001;1:141-149.
47. Mattingly RR, Gibbs RA, Menard RE, Reiners JJ Jr. Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. J Pharmacol Exp Ther 2002;303:74-81.
48. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol 2008;75:405-413.
49. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 2002;277:10678-10682.
50. Corpataux JM, Naik J, Porter KE, London NJ. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res 2005;129:52-56.
51. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
52. Park MJ, Kwak HJ, Lee HC, et al. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. J Biol Chem 2007;282:30485-30496.
53. Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S. The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J Am Soc Nephrol 2003;14:1427-1434.